At this AEI event, panelists will comment on the CDC's future with vaccines, drawing from experiences in public health, policy, and industry.

The current system of supplying vaccines appears to be in a state of crisis. While immunization rates among children are high, there have been periodic shortages of vaccines. In addition, there are few incentives to develop new vaccines, and a declining number of manufacturers. That has raised concerns that we...

Reviewing "The Myth of The Paperless Office" for the New Yorker in 2002, Malcolm Gladwell argued that if the computer had come first, and paper didn't exist, someone would have had to invent it.  Paper, it turns out, is a lot more useful than we typically appreciate.

Bioterrorism attacks using anthrax occurred almost simultaneously with shortages of widely used vaccines. Because vaccines are essential to biodefense, these two disturbing episodes are ominously linked. The topic of the morning discussion will be whether our recent vaccine shortage is a unique, one-time problem or rather caused by systemic obstacles...

Vaccine development requires partnership between government and industry because of the different resources, perspectives, and skills that each brings to the table.

The current flu vaccine shortage underscores a much greater problem: vaccine development in the U.S. is stagnant, and many producers have exited the market altogether. While some public health officials believe the solution lies in increased government control of development and production, industry officials point to government control—in the form...

Ernst R. Berndt and Anjli C. Warner discuss their new book, U.S. Markets for Vaccines: Characteristics, Case Studies, and Controversies.

AEI's Scott Gottlieb argues that the focus of legislation should not be on creating employment benefits specifically targeted to H1N1, but instead on ways to mitigate risks in future pandemics by providing Americans with early vaccinations.